




Instance: composition-en-6993a685d10576536183960090af1fdd
InstanceOf: CompositionUvEpi
Title: "Composition for anagrelide Package Leaflet"
Description:  "Composition for anagrelide Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/17/1256/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp6993a685d10576536183960090af1fdd)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - anagrelide"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Anagrelide Viatris is and what it is used for </li>
<li>What you need to know before you take Anagrelide Viatris </li>
<li>How to take Anagrelide Viatris </li>
<li>Possible side effects </li>
<li>How to store Anagrelide Viatris </li>
<li>Contents of the pack and other information </li>
</ol> </div>"""   
          

* section[=].section[+]
  * title =  "1. What anagrelide is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What anagrelide is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Anagrelide Viatris contains the active substance, anagrelide. Anagrelide is a medicine which interferes 
with the development of platelets. It reduces the number of platelets produced by the bone marrow, 
which results in a decrease in the platelet count in the blood towards a more normal level. For this 
reason, it is used to treat patients with essential thrombocythaemia. </p>
<p>Essential thrombocythaemia is a condition which occurs when the bone marrow produces too many of 
the blood cells known as platelets. Large numbers of platelets in the blood can cause serious problems 
with blood circulation and clotting. </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take anagrelide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take anagrelide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Anagrelide Viatris 
* If you are allergic to anagrelide or any of the other ingredients of this medicine (listed in 
section 6). An allergic reaction may be recognised as a rash, itching, swollen face or lips, or 
shortness of breath; 
* If you have moderate or severe liver problems; 
* If you have moderate or severe kidney problems. </p>
<p>Warnings and precautions 
Talk to your doctor before taking Anagrelide Viatris: 
* If you have or think you might have a problem with your heart; 
* If you were born with or have family history of prolonged QT interval (seen on ECG, electrical 
recording of the heart), or you are taking other medicines that result in abnormal ECG changes 
or if you have low levels of electrolytes, e.g., potassium, magnesium or calcium (see section 
 Other medicines and Anagrelide Viatris ); 
* If you have any problems with your liver or kidneys. </p>
<p>In combination with acetylsalicylic acid (a substance present in many medicines used to relieve pain 
and lower fever, as well as to prevent blood clotting, also known as aspirin), there is an increased risk </p>
<p>of major haemorrhages (bleeding) (see section  Other medicines and Anagrelide Viatris ). </p>
<p>While taking Anagrelide Viatris, you should take the exact dose prescribed by your doctor. Do not 
stop taking the medicine without first talking to your doctor. Do not abruptly stop taking this medicine 
without consulting your doctor. Abrupt withdrawal of medicine may lead to increased risk of stroke. </p>
<p>Signs and symptoms of stroke may include sudden numbness or weakness in the face, arm, or leg, 
especially on one side of the body, sudden confusion, trouble speaking, or difficulty understanding 
speech, sudden trouble seeing in one or both eyes, sudden trouble walking, dizziness, loss of balance, 
or lack of coordination and sudden severe headache with no known cause.  Please seek immediate 
medical help. </p>
<p>Children and adolescents 
There is limited information on the use of anagrelide in children and adolescents and therefore this 
medicine should be used with caution. </p>
<p>Other medicines and Anagrelide Viatris 
Tell your doctor or pharmacist if you are taking or have recently taken or might take any other 
medicines. </p>
<p>Tell your doctor if you are taking any of the following medicines: 
* Medicines that can alter your heart rhythm, e.g., sotalol, amiodarone; 
* Fluvoxamine, used to treat depression; 
* Certain types of antibiotic, such as enoxacin, used to treat infections; 
* Theophylline, used to treat severe asthma and breathing problems; 
* Medicines used to treat heart disorders, for example, milrinone, enoximone, amrinone, 
olprinone and cilostazol; 
* Acetylsalicylic acid (a substance present in many medicines used to relieve pain and lower 
fever, as well as to prevent blood clotting, also known as aspirin); 
* Other medicines used to treat conditions affecting the platelets in your blood, e.g., clopidogrel; 
* Omeprazole, used to reduce the amount of acid produced in the stomach; 
* Oral contraceptives: If you experience bad diarrhoea whilst taking this medicine, it may reduce 
how well the oral contraceptive works and use of an extra method of contraception is 
recommended (e.g., condom). See the instructions in the patient leaflet of the contraceptive pill 
you are taking. </p>
<p>Anagrelide or these medicines may not work properly if taken together. </p>
<p>If you are not sure, speak to your doctor or pharmacist for advice. </p>
<p>Pregnancy and breast-feeding 
Tell your doctor if you are pregnant or are planning to become pregnant. Anagrelide Viatris should not 
be taken by pregnant women. Women who are at risk of becoming pregnant should make sure that 
they are using effective contraception when taking anagrelide. Speak to your doctor if you need advice 
with contraception. </p>
<p>Tell your doctor if you are breast-feeding or if you are planning to breast-feed your baby. Anagrelide 
Viatris should not be taken while breast-feeding. You must stop breast-feeding if you are taking 
Anagrelide Viatris. </p>
<p>Driving and using machines 
Dizziness has been reported by some patients taking anagrelide. Do not drive or use machines if you 
feel dizzy. </p>
<p>Anagrelide Viatris contains lactose and sodium </p>
<p>This medicine contains lactose. If you have been told by your doctor that you have an intolerance to 
some sugars, contact your doctor before taking this medicine. </p>
<p>This medicine contains less than 1 mmol sodium (23 mg) per capsule, that is to say essentially 
 sodium-free . </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take anagrelide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take anagrelide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take Anagrelide Viatris exactly as your doctor has told you. Check with your doctor or 
pharmacist if you are not sure. </p>
<p>The amount of anagrelide that people take can be different, and this depends on your condition. Your 
doctor will prescribe the best dose for you. </p>
<p>The usual starting dose of this medicine is 1 mg. You take this dose as one capsule of 0.5 mg twice a 
day, for at least a week. After this time, your doctor may either increase or decrease the number of 
capsules that you take to find the dose best suited to you and which treats your condition most 
effectively. </p>
<p>Your capsules should be swallowed whole with a glass of water. Do not crush the capsules or dilute 
the contents in a liquid. You can take the capsules with food or after a meal or on an empty stomach. It 
is best to take the capsule(s) at the same time every day. </p>
<p>Do not take more or less capsules than your doctor has recommended. Do not stop taking the 
medicine without first talking to your doctor. You should not suddenly stop taking this medicine on 
your own. </p>
<p>Your doctor will ask you to have blood tests at regular intervals to check that your medicine is 
working effectively and that your liver and kidneys are working well. </p>
<p>If you take more Anagrelide Viatris than you should 
If you take more Anagrelide Viatris than you should or if someone else has taken your medicine, tell a 
doctor or pharmacist immediately. Show them the pack of Anagrelide Viatris. </p>
<p>If you forget to take Anagrelide Viatris 
Take your capsules as soon as you remember. Take your next dose at the usual time. Do not take a 
double dose to make up for a forgotten dose. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. If you are 
worried, speak to your doctor. </p>
<p>Serious side effects 
Uncommon: Heart failure (signs include shortness of breath, chest pain, swelling of the legs due to 
fluid build-up), severe problem with the rate or rhythm of the heartbeat (ventricular tachycardia, 
supraventricular tachycardia or atrial fibrillation), inflammation of the pancreas which causes severe 
abdominal and back pain (pancreatitis), vomiting blood or passing bloody or black stools, severe 
reduction in blood cells which can cause weakness, bruising, bleeding or infections (pancytopenia), 
increased pressure in the lung arteries (signs include shortness of breath, swelling in legs or ankles and 
lips and skin can turn bluish colour). 
Rare: Kidney failure (when you pass little or no urine), heart attack. </p>
<p>If you notice any of these side effects, contact your doctor immediately. </p>
<p>Other possible side effects 
Very common side effects (may affect more than 1 in 10 people): 
Headache. </p>
<p>Common side effects (may affect up to 1 in 10 people): 
Dizziness, tiredness, rapid heartbeat, irregular or strong heartbeat (palpitations), feeling sick (nausea), 
diarrhoea, stomach pain, wind, being sick (vomiting), reduction in red blood cell count (anaemia), 
fluid retention or rash. </p>
<p>Uncommon side effects (may affect up to 1 in 100 people): 
A feeling of weakness or feeling unwell, high blood pressure, irregular heartbeat, fainting, chills or 
fever, indigestion, loss of appetite, constipation, bruising, bleeding, swelling (oedema), weight loss, 
muscle aches, painful joints, back pain, decreased or loss of feeling or sensation such as numbness, 
especially in the skin, abnormal feeling or sensation such as tingling and  pins and needles , 
sleeplessness, depression, confusion, nervousness, dry mouth, loss of memory, breathlessness, 
nosebleed, serious lung infection with fever, shortness of breath, cough, phlegm; hair loss, skin itching 
or discolouration, impotence, chest pain, reduction in blood platelets, which increases the risk of 
bleeding or bruising (thrombocytopenia), accumulation of fluid around the lungs or an increase in liver 
enzymes. Your doctor may do a blood test which may show an increase in your liver enzymes. </p>
<p>Rare side effects (may affect up to 1 in 1,000 people): 
Bleeding gums, weight gain, severe chest pain (angina pectoris), heart muscle disease, (signs include 
fatigue, chest pain and palpitations), enlarged heart, accumulation of fluid around the heart, painful 
spasm of the blood vessels on the heart (while resting, usually at night or early morning) (Prinzmetal 
angina), loss of coordination, difficulty in speaking, dry skin, migraine, visual disturbances or double 
vision, ringing in the ears, dizziness on standing up (especially when getting up from a sitting or lying 
position), increased need to pass water at night, pain,  flu-like  symptoms, sleepiness, widening of 
blood vessels, inflammation of the large bowel (signs include: diarrhoea, usually with blood and 
mucus, stomach pain, fever), inflammation of the stomach (signs include: pain, nausea, vomiting), 
area of abnormal density in the lung, increased creatinine level in blood tests, which may be a sign of 
kidney problems. </p>
<p>The following side effects have been reported but it is not known exactly how often they occur: 
* Potentially life-threatening, irregular heartbeat (Torsade de pointes); 
* Inflammation of the liver, symptoms include nausea, vomiting, itching, yellowing of the skin 
and eyes, discoloration of stool and urine (hepatitis); 
* Lung inflammation (signs include fever, coughing, difficulty breathing, wheezing; which causes 
scaring of the lungs) (allergic alveolitis, including interstitial lung disease, pneumonitis); 
* Inflammation of the kidneys (tubulointerstitial nephritis). 
* Stroke (see section 2). </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects, you can help provide more information on the safety 
of this medicine. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store anagrelide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store anagrelide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the carton and bottle label after EXP. 
The expiry date refers to the last day of that month. </p>
<p>Store in the original package in order to protect from light and moisture.  </p>
<p>This medicinal product does not require any special temperature storage conditions. </p>
<p>If your doctor stops your medicine, do not keep any leftover capsules unless your doctor tells you to. 
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Anagrelide Viatris contains 
The active substance is anagrelide. Each capsule contains anagrelide hydrochloride monohydrate 
equivalent to 0.5 mg anagrelide. 
The other ingredients are lactose, croscarmellose sodium, povidone, microcrystalline cellulose, 
magnesium stearate, gelatin and titanium dioxide(E171). See section 2  Anagrelide Viatris contains 
lactose and sodium . </p>
<p>What Anagrelide Viatris looks like and contents of the pack 
Anagrelide Viatris 0.5 mg hard capsules have a white body and cap. The capsule is filled with a white 
to off-white powder. 
The capsule size is approximately 14.3 x 5.3 mm. </p>
<p>Anagrelide Viatris is available in plastic bottles of 30 ml or 75 ml with a tamper evident, 
child-resistant closure and a desiccant. Each bottle contains 100 hard capsules. </p>
<p>Marketing Authorisation Holder 
Mylan Pharmaceuticals Limited 
Damastown Industrial Park<br />
Mulhuddart, Dublin DUBLIN 
Ireland  </p>
<p>Manufacturer 
Synthon Hispania SL 
C/ Castell  no1 
POL. Las Salinas 
Sant Boi de Llobregat 
08830 Barcelona 
Spain </p>
<p>Synthon BV<br />
Microweg 6545 CM Nijmegen<br />
The Netherlands  </p>
<p>For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder: </p>
<p>Belgi /Belgique/Belgien 
Mylan bvba/sprl 
T l/Tel: + 32 (0)2 658 61 Lietuva 
Mylan Healthcare UAB <br />
Tel: +370 5 205 1  </p>
<p>: +359 2 44 55 Luxembourg/Luxemburg 
Mylan bvba/sprl 
T l/Tel: + 32 (0)2 658 61 (Belgique/Belgien) </p>
<p>esk  republika 
Viatris CZ s.r.o. 
Tel: + 420 222 004 Magyarorsz g 
Mylan EPD Kft. 
Tel.: + 36 1 465 2Danmark 
Viatris ApS 
Tlf: +45 28 11 69 Malta 
V.J. Salomone Pharma Ltd 
Tel: + 356 21 22 01 Deutschland 
Viatris Healthcare GmbH 
Tel: +49 800 0700 Nederland 
Mylan BV 
Tel: + 31 (0)20 426 3Eesti 
BGP Products Switzerland GmbH Eesti 
filiaal 
Tel: + 372 6363 Norge 
Viatris AS 
Tlf: + 47 66 75 33  <br />
Generics Pharma Hellas  <br />
 :  +30 210 993 6 sterreich 
Arcana Arzneimittel GmbH 
Tel: +43 1 416 2Espa a 
Viatris Pharmaceuticals, S.L.U. 
Tel: + 34 900 102 Polska 
Mylan Healthcare Sp. z o.o. 
Tel.: + 48 22 546 64 France 
Viatris Sant<br />
T l: +33 4 37 25 75 Portugal 
Mylan, Lda. 
Tel: + 351 214 127 Hrvatska 
Mylan Hrvatska d.o.o.<br />
Tel: +385 1 23 50 Rom nia 
BGP Products SRL 
Tel: +40 372 579 Ireland 
Mylan Ireland Limited 
Tel: +353 1 8711Slovenija 
Viatris d.o.o. 
Tel: + 386 1 23 63  sland 
Icepharma hf. 
S mi: +354 540 8Slovensk  republika 
Viatris Slovakia s.r.o. 
Tel: +421 2 32 199 Italia 
Mylan Italia S.r.l. 
Tel: + 39 02 612 46Suomi/Finland 
Viatris OY 
Puh/Tel: +358 20 720 9<br />
Varnavas Hadjipanayis Ltd<br />
 : +357 2220 7Sverige 
Viatris AB<br />
Tel: +46 (0)8 630 19 Latvija 
Mylan Healthcare SIA 
Tel: +371 676 055 United Kingdom (Northern Ireland) 
Mylan IRE Healthcare Limited 
Tel: +353 18711This leaflet was last revised in  </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p> </div>"""      



Instance: composition-da-6993a685d10576536183960090af1fdd
InstanceOf: CompositionUvEpi
Title: "Composition for anagrelide Package Leaflet"
Description:  "Composition for anagrelide Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "EU/1/17/1256/001"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp6993a685d10576536183960090af1fdd)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - anagrelide"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional

  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>unavailable</div>"""
  * emptyReason = http://terminology.hl7.org/CodeSystem/list-empty-reason#unavailable   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at tage Anagrelide Viatris 
3. Sådan skal du tage Anagrelide Viatris 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p> </div>"""   
          

* section[=].section[+]
  * title =  "1. What anagrelide is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What anagrelide is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Anagrelide Viatris indeholder det aktive stof, anagrelid. Anagrelid er et lægemiddel, der griber ind i 
udviklingen af blodplader. Det reducerer det antal blodplader, som knoglemarven danner, hvilket 
medfører et fald i antallet af blodplader i blodet hen imod et mere normalt niveau. Derfor anvendes det 
til behandling af patienter med essentiel trombocytæmi. </p>
<p>Essentiel trombocytæmi er en tilstand, der optræder, når knoglemarven producerer for mange af de 
blodceller, der kaldes blodplader. Et stort antal blodplader i blodet kan medføre alvorlige problemer 
med blodcirkulationen og dannelse af blodpropper.  </p> </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take anagrelide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take anagrelide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Anagrelide Viatris </p>
<ul>
<li>
<p>hvis du er allergisk over for anagrelid eller et af de øvrige indholdsstoffer i Anagrelide Viatris 
(angivet i afsnit 6). En allergisk reaktion kan genkendes som udslæt, kløe, hævet ansigt eller 
læber eller stakåndethed; </p>
</li>
<li>
<p>hvis du har moderate eller alvorlige leverproblemer; </p>
</li>
<li>
<p>hvis du har moderate eller alvorlige nyreproblemer. </p>
</li>
</ul>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen, før du tager Anagrelide Viatris: </p>
<ul>
<li>
<p>Hvis du har eller mener, at du måske har et problem med hjertet; </p>
</li>
<li>
<p>Hvis du har medfødt forlænget QT-interval, eller du har det i familien (kan ses på EKG’et, en 
registrering af hjertets elektriske aktivitet), eller du tager andre lægemidler, der fører til 
unormale EKG-ændringer, eller du har lavt indhold af salte, f.eks. kalium, magnesium eller 
calcium (se afsnittet "Brug af anden medicin sammen med Anagrelide Viatris"); </p>
</li>
<li>
<p>Hvis du har problemer med lever eller nyrer. </p>
</li>
</ul>
<p>I kombination med acetylsalicylsyre (et stof, der findes i mange former for medicin og anvendes til 
smertelindring og febernedsættelse samt til at forhindre blodet i at størkne. Det kaldes også aspirin) er 
der en forøget risiko for større blødninger (se “Brug af anden medicin sammen med Anagrelide 
Viatris"). </p>
<p>Indtag altid den nøjagtige dosis af Anagrelide Viatris, som lægen har ordineret. Stop ikke med at tage 
medicinen uden først at tale med din læge. Du må ikke pludselig stoppe med at tage denne medicin 
uden at kontakte din læge, da det kan øge risikoen for slagtilfælde. </p>
<p>Søg straks lægehjælp hvis du oplever tegn og symptomer på slagtilfælde, som kan inkludere pludselig 
følelsesløshed eller slaphed i ansigt, arm eller ben, særligt i én side af kroppen, pludselig forvirring, 
taleproblemer eller problemer med at forstå tale, pludselige synsproblemer på et eller begge øjne, 
pludseligt gangbesvær, svimmelhed, tab af balance eller mangel på koordination og pludselig svær 
hovedpine uden kendt årsag. </p>
<p>Børn og unge 
Der er begrænsede oplysninger om anvendelse af anagrelid hos børn og unge. Anagrelide Viatris skal 
derfor anvendes med forsigtighed. </p>
<p>Brug af anden medicin sammen med Anagrelide Viatris 
Fortæl det altid til lægen eller apotekspersonalet, hvis du tager anden medicin, for nylig har taget 
anden medicin eller planlægger at tage anden medicin. </p>
<p>Fortæl din læge, om du tager en eller flere slags anden medicin: </p>
<ul>
<li>
<p>Medicin, der kan ændre din hjerterytme, f.eks. sotalol, amiodaron; </p>
</li>
<li>
<p>Fluvoxamin, som anvendes til behandling af depression; </p>
</li>
<li>
<p>Visse former for antibiotika, såsom enoxacin, som anvendes til behandling af infektioner; </p>
</li>
<li>
<p>Theophyllin, som anvendes til behandling af svær astma og vejrtrækningsproblemer; </p>
</li>
<li>
<p>Medicin til behandling af hjertesygdomme, f.eks. milrinon, enoximon, amrinon, olprinon og 
cilostazol; </p>
</li>
<li>
<p>Acetylsalicylsyre (et stof, der findes i mange former for medicin og anvendes til smertelindring 
og febernedsættelse samt til at forhindre blodet i at størkne. Det kaldes også aspirin); </p>
</li>
<li>
<p>Anden medicin til behandling af tilstande, der påvirker blodpladerne i dit blod, f.eks. 
clopidogrel; </p>
</li>
<li>
<p>Omeprazol, som anvendes til at reducere mængden af syre, der dannes i maven; </p>
</li>
<li>
<p>Svangerskabsforebyggende tabletter: Hvis du har kraftig diarré, mens du tager dette 
lægemiddel, kan det nedsætte virkningen af svangerskabsforebyggende tabletter, og det 
anbefales at benytte en ekstra præventionsmetode (f.eks. kondom). Se anvisninger i 
indlægssedlen for den svangerskabsforebyggende tablet, som du tager. </p>
</li>
</ul>
<p>Anagrelide Viatris eller disse lægemidler virker måske ikke korrekt, hvis de tages samtidigt. </p>
<p>Spørg lægen eller på apoteket, hvis der er noget, du er i tvivl om. </p>
<p>Graviditet og amning<br />
Tal med lægen, hvis du er gravid, har mistanke om, at du er gravid, eller planlægger at blive gravid. 
Gravide må ikke tage Anagrelide Viatris. Kvinder, der kan blive gravide, skal sikre, at de anvender 
effektiv prævention, mens de tager anagrelid. Tal med din læge, hvis du har brug for råd vedrørende 
prævention. </p>
<p>Tal med lægen, hvis du ammer eller planlægger at amme dit barn. Du må ikke tage Anagrelide Viatris, 
mens du ammer. Du skal stoppe med at amme, hvis du tager Anagrelide Viatris. </p>
<p>Trafik- og arbejdssikkerhed 
Nogle patienter i behandling med anagrelid har rapporteret om svimmelhed. Kør ikke bil og betjen 
ikke maskiner, hvis du føler dig svimmel. </p>
<p>Anagrelide Viatris indeholder lactose og natrium 
Dette lægemiddel indeholder lactose. Kontakt lægen, før du tager denne medicin, hvis lægen har 
fortalt dig, at du ikke tåler visse sukkerarter. </p>
<p>Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. kapsel, dvs. det er i det 
væsentlige natriumfrit. </p> </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take anagrelide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take anagrelide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller 
apotekspersonalet. </p>
<p>Det er forskelligt, hvilken mængde anagrelid forskellige mennesker kan indtage, og dette afhænger af 
din tilstand. Din læge vil ordinere den bedste dosis til dig. </p>
<p>Den sædvanlige startdosis af dette lægemiddel er 1 mg. Du tager denne dosis som en kapsel med 
0,5 mg to gange dagligt i mindst én uge. Derefter kan din læge enten øge eller reducere antallet af 
kapsler, du skal tage, for at finde den dosis, der bedst passer dig, og som behandler din tilstand mest 
effektivt. </p>
<p>Du skal sluge kapslerne hele med et glas vand. Du må ikke knuse kapslerne eller fortynde indholdet 
med væske. Du kan tage kapslerne med mad, efter et måltid eller på tom mave. Det er bedst at tage 
kapslerne på samme tidspunkt hver dag. </p>
<p>Tag ikke flere eller færre kapsler, end din læge har anbefalet. Stop ikke med at tage medicinen uden 
først at tale med din læge. Du må ikke pludselig stoppe med at tage denne medicin på egen hånd. </p>
<p>Din læge vil bede dig få taget blodprøver med jævne mellemrum for at kontrollere, at medicinen 
virker effektivt, og at din lever og nyrer fungerer, som de skal. </p>
<p>Hvis du har taget for meget Anagrelide Viatris 
Hvis du har taget for meget Anagrelide Viatris, eller hvis en anden har taget din medicin, skal du 
straks underrette din læge eller apoteket. Vis dem Anagrelide Viatris emballagen. </p>
<p>Hvis du har glemt at tage Anagrelide Viatris 
Tag kapslerne, så snart du kommer i tanker om det. Tag næste dosis på det sædvanlige tidspunkt. 
Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis. </p> </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. 
Hvis du er bekymret herfor, skal du kontakte din læge. </p>
<p>Alvorlige bivirkninger: 
Ikke almindelig: Hjertesvigt (tegn omfatter stakåndethed, brystsmerter, hævede ben på grund af 
væskeophobning), alvorlige problemer med hjerteslagets frekvens eller rytme (ventrikulær takykardi, 
supraventrikulær takykardi eller atrieflimmer), betændelse i bugspytkirtlen, hvilket forårsager svære 
mave- og rygsmerter (pankreatitis), opkastning af blod eller blodig eller sort afføring, alvorligt nedsat 
antal blodlegemer, hvilket kan forårsage svaghed, blå mærker, blødning eller infektioner 
(pancytopeni), forhøjet blodtryk i lungearterierne (tegn omfatter stakåndethed, hævede ben eller ankler 
og blålige læber og hud). 
Sjælden: Nyresvigt (du udskiller kun lidt eller ingen urin), hjerteanfald. </p>
<p>Kontakt straks din læge, hvis du bemærker nogle af disse bivirkninger. </p>
<p>Andre bivirkninger 
Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 personer): 
Hovedpine. </p>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer): 
Svimmelhed, træthed, hurtigt hjerteslag, uregelmæssige eller kraftige hjerteslag (hjertebanken), 
kvalme, diarré, mavesmerter, luft i maven, opkastning, nedsat antal røde blodceller (anæmi), væske i 
kroppen eller udslæt. </p>
<p>Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 personer): 
En følelse af svaghed eller utilpashed, forhøjet blodtryk, uregelmæssigt hjerteslag, besvimelse, 
kuldegysninger eller feber, fordøjelsesbesvær, manglende appetit, forstoppelse, blå mærker, blødning, 
hævelse (ødem), vægttab, muskelsmerter, smerter i led, rygsmerter, nedsat eller manglende følesans, 
såsom følelsesløshed, især i huden, unormal følesans eller stikkende og prikkende fornemmelse, 
søvnløshed, depression, forvirring, nervøsitet, tør mund, hukommelsestab, stakåndethed, næseblod, 
alvorlig lungeinfektion med feber, åndenød, hoste, slim, hårtab, hudkløe eller misfarvning af huden, 
impotens, brystsmerter, nedsat antal blodplader, hvilket øger risikoen for blødning eller blå mærker 
(trombocytopeni), væskeophobning rundt om lungerne eller forhøjede leverenzymer. Din læge vil 
muligvis tage en blodprøve, som eventuelt kan vise forhøjede leverenzymer. </p>
<p>Sjældne bivirkninger (kan forekomme hos op til 1 ud af 1 000 personer): 
Blødende gummer, vægtforøgelse, svære brystsmerter (angina pectoris), sygdom i hjertemusklen (tegn 
omfatter træthed, brystsmerter og hjertebanken), forstørret hjerte, væskeophobning rundt om hjertet, 
smertefuld krampe i hjertets blodårer (i hvile, som regel om natten eller tidligt om morgenen) 
(Prinzmetal angina), koordinationstab, talevanskeligheder, tør hud, migræne, synsforstyrrelser eller 
dobbeltsyn, ringen for ørerne, svimmelhed, når du står op (især når du rejser dig fra siddende eller 
liggende stilling), øget vandladningstrang om natten, smerte, ’influenzalignende’ symptomer, 
søvnighed, udvidelse af blodkarrene, tyktarmsbetændelse (tegn omfatter: diarré, normalt med blod og 
slim, mavesmerter, feber), betændelseslignende reaktion (inflammation) i maven (tegn omfatter 
smerter, kvalme, opkastning), områder med unormal tæthed af lungevæv, forhøjet kreatinin i 
blodprøver, hvilket kan være tegn på nyreproblemer. </p>
<p>Følgende bivirkninger er blevet indberettet, men det vides ikke præcist, hvor ofte de 
forekommer: </p>
<ul>
<li>
<p>Uregelmæssig hjerterytme, der kan være livstruende (torsades de pointes); </p>
</li>
<li>
<p>Leverbetændelse, symptomer omfatter kvalme, opkastning, kløe, gulfarvning af hud og øjne, 
misfarvning af afføring eller urin (hepatitis); </p>
</li>
<li>
<p>Betændelseslignende reaktion (inflammation) i lungerne (tegn omfatter feber, hoste, 
vejrtrækningsbesvær, hvæsende vejrtrækning; som danner arvæv i lungerne) (allergisk alveolitis, 
herunder interstitiel lungesygdom, pneumonitis); </p>
</li>
<li>
<p>Inflammation i nyrerne (tubulointerstitiel nefritis). </p>
</li>
<li>
<p>Slagtilfælde (se afsnit 2). </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel. </p> </div>"""      
        
* section[=].section[+]
  * title = "5. How to store anagrelide"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store anagrelide"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på æsken og flaskens etiket efter EXP.<br />
Udløbsdatoen er den sidste dag i den nævnte måned. </p>
<p>Opbevares i den originale yderpakning for at beskytte mod lys og fugt. 
Der er ingen særlige krav vedrørende opbevaringstemperaturer for dette lægemiddel  </p>
<p>Hvis din læge standser din medicinering, må du ikke beholde eventuelle resterende kapsler, 
medmindre din læge beder dig om det. 
Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet eller skraldespanden. </p> </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Anagrelide Viatris indeholder:</p>
<ul>
<li>Aktivt stof: anagrelid. Hver kapsel indeholder anagrelidhydrochloridmonohydrat svarende til 
0,5 mg anagrelid. </li>
<li>Øvrige indholdsstoffer: Lactose, croscarmellosenatrium, povidon, mikrokrystallinsk cellulose, 
magnesiumstearat, gelatine og titandioxid (E171). Se afsnit 2 “Anagrelide Viatris indeholder 
lactose og natrium". </li>
</ul>
<p>Udseende og pakningsstørrelser 
Anagrelide Viatris 0,5 mg hårde kapsler har en hvid underdel og overdel. Kapslen er fyldt med et 
hvidt til råhvidt pulver. 
Størrelsen på kapslen er ca. 14,3 x 5,3 mm. </p>
<p>Anagrelide Viatris fås i plastflasker på 30 ml eller 75 ml med et anbruds- og børnesikret låg og et 
tørremiddel. Flasken indeholder 100 hårde kapsler. </p>
<p>Indehaver af markedsføringstilladelsen 
Viatris Limited 
Damastown Industrial Park<br />
Mulhuddart, Dublin 15<br />
DUBLIN 
Irland  </p>
<p>Fremstiller 
Synthon Hispania SL 
C/ Castelló no1 
POL. Las Salinas 
Sant Boi de Llobregat 
08830 Barcelona 
Spanien </p>
<p>Synthon BV<br />
Microweg 22<br />
6545 CM Nijmegen<br />
Holland  </p>
<p>Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen: </p>
<p>België/Belgique/Belgien 
Viatris 
Tél/Tel: + 32 (0)2 658 61<br />
Lietuva 
Viatris UAB <br />
Tel: +370 5 205 1 
България 
Майлан ЕООД 
Тел: +359 2 44 55<br />
Luxembourg/Luxemburg 
Viatris 
Tél/Tel: + 32 (0)2 658 61 (Belgique/Belgien) </p>
<p>Česká republika 
Viatris CZ s.r.o. 
Tel: + 420 222 004<br />
Magyarország 
Viatris Healthcare Kft. 
Tel.: + 36 1 465 2 
Danmark 
Viatris ApS 
Tlf: +45 28 11 69 Malta 
V.J. Salomone Pharma Ltd 
Tel: + 356 21 22 01<br />
Deutschland 
Viatris Healthcare GmbH 
Tel: +49 800 0700 Nederland 
Mylan BV 
Tel: + 31 (0)20 426 3 
Eesti 
Viatris OÜ<br />
Tel: + 372 6363  </p>
<p>Norge 
Viatris AS 
Tlf: + 47 66 75 33  </p>
<p>Ελλάδα<br />
Viatris Hellas Ltd 
Τηλ:  +30 2100 100<br />
Österreich 
Arcana Arzneimittel GmbH 
Tel: +43 1 416 2 
España 
Viatris Pharmaceuticals, S.L. 
Tel: + 34 900 102<br />
Polska 
Viatris Healthcare Sp. z o.o. 
Tel.: + 48 22 546 64<br />
France 
Viatris Santé 
Tél: +33 4 37 25 75<br />
Portugal 
Mylan, Lda. 
Tel: + 351 214 127<br />
Hrvatska 
Viatris Hrvatska d.o.o.<br />
Tel: +385 1 23 50<br />
România 
BGP Products SRL 
Tel: +40 372 579<br />
Ireland 
Mylan Ireland Limited 
Tel: +353 1 8711600  </p>
<p>Slovenija 
Viatris d.o.o. 
Tel: + 386 1 23 63<br />
Ísland 
Icepharma hf. 
Sími: +354 540 8 
Slovenská republika 
Viatris Slovakia s.r.o. 
Tel: +421 2 32 199 Italia 
Viatris Italia S.r.l. 
Tel: + 39 (0) 2 612 46 
Suomi/Finland 
Viatris Oy 
Puh/Tel: +358 20 720 9 </p>
<p>Κύπρος 
GPA Pharmaceuticals Ltd<br />
Τηλ: +357 22863 
Sverige 
Viatris AB<br />
Tel: +46 (0)8 630 19<br />
Latvija 
Viatris SIA 
Tel: +371 676 055<br />
United Kingdom (Northern Ireland) 
Mylan IRE Healthcare Limited 
Tel: +353 18711600  </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside http://www.ema.europa.eu. Der er også links til andre websteder om sjældne sygdomme 
og om, hvordan de behandles. </p>
<p>Indlægsseddel: Information til patienten </p>
<p>Anagrelide Viatris 1 mg hårde kapsler </p>
<p>anagrelid </p>
<p>Læs denne indlægsseddel grundigt, inden du begynder at tage dette lægemiddel, da den 
indeholder vigtige oplysninger. 
- Gem indlægssedlen. Du kan få brug for at læse den igen. 
- Spørg lægen eller apotekspersonalet, hvis der er mere, du vil vide. 
- Lægen har ordineret dette lægemiddel til dig personligt. Lad derfor være med at give medicinen 
til andre. Det kan være skadeligt for andre, selvom de har de samme symptomer, som du har. 
- Kontakt lægen eller apotekspersonalet, hvis du får bivirkninger, herunder bivirkninger, som 
ikke er nævnt i denne indlægsseddel. Se afsnit 4. Se den nyeste indlægsseddel på www.indlaegsseddel.dk. </p> </div>"""      





                    
Instance: bundlepackageleaflet-en-6993a685d10576536183960090af1fdd
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for anagrelide Package Leaflet for language en"
Description: "ePI document Bundle for anagrelide Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-6993a685d10576536183960090af1fdd"
* entry[0].resource = composition-en-6993a685d10576536183960090af1fdd

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp6993a685d10576536183960090af1fdd"
* entry[=].resource = mp6993a685d10576536183960090af1fdd
                            
                    
Instance: bundlepackageleaflet-da-6993a685d10576536183960090af1fdd
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for anagrelide Package Leaflet for language da"
Description: "ePI document Bundle for anagrelide Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-6993a685d10576536183960090af1fdd"
* entry[0].resource = composition-da-6993a685d10576536183960090af1fdd

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp6993a685d10576536183960090af1fdd"
* entry[=].resource = mp6993a685d10576536183960090af1fdd
                            
                    



Instance: mp6993a685d10576536183960090af1fdd
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Anagrelide Viatris 0.5 mg hard capsules"
Description: "Anagrelide Viatris 0.5 mg hard capsules"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/17/1256/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Anagrelide Viatris 0.5 mg hard capsules"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 6993a685d10576536183960090af1fddListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "anagrelide"

* status = #current
* mode = #working

* title = "List of all ePIs associated with anagrelide"

* subject = Reference(mp6993a685d10576536183960090af1fdd)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#anagrelide "anagrelide"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-6993a685d10576536183960090af1fdd) // anagrelide en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-6993a685d10576536183960090af1fdd) // anagrelide da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-6993a685d10576536183960090af1fdd
InstanceOf: List

* insert 6993a685d10576536183960090af1fddListRuleset
    